Your browser doesn't support javascript.
loading
Further Quinolizidine Derivatives as Antiarrhythmic Agents- 3.
Tasso, Bruno; Mattioli, Laura Beatrice; Tonelli, Michele; Boido, Vito; Chiarini, Alberto; Sparatore, Fabio; Budriesi, Roberta.
Afiliação
  • Tasso B; Department of Pharmacy, University of Genova, 16132 Genova, Italy.
  • Mattioli LB; Food Chemistry and Nutraceutical Research Unit, Department of Pharmacy & Biotechnology, Alma Mater Studiorum, University of Bologna, 40126 Bologna, Italy.
  • Tonelli M; Department of Pharmacy, University of Genova, 16132 Genova, Italy.
  • Boido V; Department of Pharmacy, University of Genova, 16132 Genova, Italy.
  • Chiarini A; Food Chemistry and Nutraceutical Research Unit, Department of Pharmacy & Biotechnology, Alma Mater Studiorum, University of Bologna, 40126 Bologna, Italy.
  • Sparatore F; Department of Pharmacy, University of Genova, 16132 Genova, Italy.
  • Budriesi R; Food Chemistry and Nutraceutical Research Unit, Department of Pharmacy & Biotechnology, Alma Mater Studiorum, University of Bologna, 40126 Bologna, Italy.
Molecules ; 28(19)2023 Oct 03.
Article em En | MEDLINE | ID: mdl-37836759
ABSTRACT
Fourteen quinolizidine derivatives, structurally related to the alkaloids lupinine and cytisine and previously studied for other pharmacological purposes, were presently tested for antiarrhythmic, and other cardiovascular effects on isolated guinea pig heart tissues in comparison to well-established reference drugs. According to their structures, the tested compounds are assembled into three subsets (a) N-(quinolizidinyl-alkyl)-benzamides; (b) 2-(benzotriazol-2-yl)methyl-1-(quinolizidinyl)alkyl-benzimidazoles; (c) N-substituted cytisines. All compounds but two displayed antiarrhythmic activity that was potent for compounds 4, 1, 6, and 5 (in ascending order). The last compound (N-(3,4,5-trimethoxybenzoyl)aminohomolupinane) was outstanding, exhibiting a nanomolar potency (EC50 = 0.017 µM) for the increase in the threshold of ac-arrhythmia. The tested compounds shared strong negative inotropic activity; however, this does not compromise the value of their antiarrhythmic action. On the other hand, only moderate or modest negative chronotropic and vasorelaxant activities were commonly observed. Compound 5, which has high antiarrhythmic potency, a favorable cardiovascular profile, and is devoid of antihypertensive activity in spontaneously hypertensive rats, represents a lead worthy of further investigation.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esparteína / Alcaloides / Quinolizidinas Limite: Animals Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esparteína / Alcaloides / Quinolizidinas Limite: Animals Idioma: En Ano de publicação: 2023 Tipo de documento: Article